Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Searching News Database:
CAM2038
HSMN NewsFeed - 4 Jun 2019
Braeburn Announces Publication of Phase 3 Study Results Showing Long-term Safety and Effectiveness of BRIXADI(TM) (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Biopharmaceuticals
HSMN NewsFeed - 21 Sep 2018
CHMP Recommends Approval of Buvidal(R) (CAM2038) for the Treatment of Opioid Dependence
Biopharmaceuticals
Regulatory
HSMN NewsFeed - 13 Jun 2017
Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE(R) in Canada for Opioid Drug Dependence
Biopharmaceuticals
Drug Delivery
Regulatory
HSMN NewsFeed - 2 May 2017
Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038
Biopharmaceuticals
HSMN NewsFeed - 5 Apr 2016
Braeburn Pharmaceuticals and Camurus Announce Enrollment Goals Reached in Two Pivotal Phase 3 Trials of Cam2038 for Treatment of Opioid Dependence
Biopharmaceuticals
HSMN NewsFeed - 30 Dec 2015
Braeburn Pharmaceuticals and Camurus Enroll First Patient in a Phase 3 Efficacy Trial of Long-acting Treatment for Opioid Dependence
Biopharmaceuticals
Return to NewsFeed
